






1/7

*Fig. 1**Fig. 2*

2/7

*Fig. 3A**Fig. 3B**Fig. 5*








Fig. 4

4/7

*Fig. 6**Fig. 7*

*Fig. 8*

*MTX is significantly different from control for the rest of the protocol.

** Compound 1 is significantly different from the control.

Fig. 9

6/7





Fig. 10



Inflammation significantly inferior to control

Compound 19a IV: Days 1, 2, 3, 4, 5, 6, 12, 13, 14, 15, 16, 18 and 19

MTX: Days 5, 15, 16, 17, 18, 19 and 21

Compound 19a PO: Days 1, 3, 5 and 6


Compound 1 PO: Days 4, 5 and 16

Compound 1 IV: Days 16 and 19

—◆— Control
 —■— MTX
 —▲— Compound 1-IV
 —■— Compound 19a-IV
 —×— Compound 1-PO
 —○— Compound 19a-PO

Fig. 11

7/7



Inflammation significantly inferior to control

Compound 19a IV: Days 13, 14, 15, 16, 18 and 20.

Methotrexate: Days 14, 15, 16, 18 and 20.

Compound 19a PO: Days 13, 14, 15, 16, 19, 20, 21 and 22.

—◆— Control
 —■— Methotrexate
 —▲— Compound 19a-IV
 —○— Compound 19a-PO

Fig. 12




Fig. 13

BEST AVAILABLE COPY